Trial Profile
MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Apr 2012 Actual patient number 8 added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.